购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Antibacterial
    (2)
  • Antibiotic
    (2)
  • Others
    (1)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 5日内发货
    (1)
  • 35日内发货
    (2)
  • 10-14周
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "bacteria,oral active"的结果
筛选
搜索结果
TargetMol产品目录中 "

bacteria,oral active

"的结果
  • 抑制剂&激动剂
    5
    TargetMol | Inhibitors_Agonists
  • 同位素
    2
    TargetMol | Isotope_Products
  • Chloramphenicol palmitate
    氯霉素棕榈酸酯
    T20525530-43-8
    Chloramphenicol palmitate 是一种广谱抗生素,对革兰氏阳性和革兰氏阴性细菌具有活性。 Chloramphenicol palmitate 可用于在含有氯霉素抗性基因的转化细胞中作为细菌选择剂的研究。
    • ¥ 133
    In stock
    规格
    数量
  • Cefpodoxime proxetil
    头孢泊肟酯
    T499887239-81-4
    Cefpodoxime Proxetil 是一种口服的广谱型抗生素。它与青霉素结合蛋白结合,抑制肽聚糖的合成,干扰细菌细胞壁的生物合成。
    • ¥ 108
    In stock
    规格
    数量
  • Octanoic Acid-13C
    T3569859669-16-8
    Octanoic acid-13C is intended for use as an internal standard for the quantification of octanoic acid by GC- or LC-MS. Octanoic acid is a medium-chain saturated fatty acid. It has been found in Teleme cheeses made from goat, ovine, or bovine milk.1 Octanoic acid is active against the bacteria S. mutans, S. gordonii, F. nucleatum, and P. gingivalis (IC80s = <125, <125, 1,403, and 2,294 μM, respectively).2 Levels of octanoic acid are increased in the plasma of patients with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, an inborn error of fatty acid metabolism characterized by hypoketotic hypoglycemia, medium-chain dicarboxylic aciduria, and intolerance to fasting.3,4 |1. Mallatou, H., Pappa, E., and Massouras, T. Changes in free fatty acids during ripening of Teleme cheese made with ewes', goats', cows' or a mixture of ewes' and goats' milk. Int. Dairy J. 13(1-3), 211-219 (2003).|2. Hyang, C.B., Alimova, Y., Myers, T.M., et al. Short- and medium-chain fatty acids exhibit antimicrobial activity for oral microorganisms. Arch. Oral Biol. 56(7), 650-654 (2011).|3. Onkenhout, W., Venizelos, V., van der Poel, P.F.H., et al. Identification and quantification of intermediates of unsaturated fatty acid metabolism in plasma of patients with fatty acid oxidation disorders. Clin. Chem. 41(10), 1467-1474 (1995).|4. Rinaldo, P., O'Shea, J.J., Coates, P.M., et al. Medium-chain acyl-CoA dehydrogenase deficiency. Diagnosis by stable-isotope dilution measurement of urinary n-hexanoylglycine and 3-phenylpropionylglycine. N. Engl. J. Med. 319(20), 1308-1313 (1988).
    • ¥ 822
    35日内发货
    规格
    数量
  • OPC-167832
    T378801883747-71-4
    OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg ml) and Kurono (MIC: 0.0005 μg ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1 2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg kg to 2.5 mg kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.
    • ¥ 1950
    5日内发货
    规格
    数量
  • Cefpodoxime proxetil-d3
    头孢泊肟酯-d3
    TMID-0290
    Cefpodoxime proxetil-d3 是 Cefpodoxime proxetil 的氘代化合物。Cefpodoxime proxetil 的 CAS 号为 87239-81-4。Cefpodoxime Proxetil 是一种口服的广谱型抗生素。它与青霉素结合蛋白结合,抑制肽聚糖的合成,干扰细菌细胞壁的生物合成。
    • 待询
    35日内发货
    规格
    数量